Arcturus Therapeutics and Thermo Fisher will collaborate to support Phase 3 development and potential commercialization of ARCT-032, the company’s investigational mRNA therapy for cystic fibrosis. The partnership with Thermo Fisher is a modest positive for execution and commercialization prospects, but the announcement does not specify clinical results or financial terms.
Arcturus Therapeutics and Thermo Fisher will collaborate to support Phase 3 development and potential commercialization of ARCT-032, the company’s investigational mRNA therapy for cystic fibrosis. The partnership with Thermo Fisher is a modest positive for execution and commercialization prospects, but the announcement does not specify clinical results or financial terms.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
